Adverum Biotechnologies (ADVM) reported results from the 26-week interim analysis of the LUNA Phase 2 trial of Ixo-vec in patients with wet age-related macular degeneration. Adverum said the analysis showed that Ixo-vec has a potential best-in-class product profile, combining a favorable safety profile and an industry-leading proportion of patients who are free of injections, supporting the company's selection of the 6E10 dose with a local prophylactic regimen for Phase 3 pivotal studies. Over the next couple quarters, the company plans to present data at 9 month and 1 year timepoints.
"The LUNA trial was designed to answer a key question - whether lower doses of Ixo-vec combined with enhanced prophylactic regimens could demonstrate a product profile consistent with or better than that demonstrated in OPTIC. The landmark 6-month interim analysis has achieved this objective," said Star Seyedkazemi, chief development officer of Adverum.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.